1.To examine the sensitivity and specificity of the multiplex immunoassay directed at a bladder cancer-associated signature in voided urine samples ability s to predict treatment response in patients with intermediate/high risk NMIBC treated with intravesical BCG. 2.To compare the sensitivity and specificity of the multiplex immunoassay to a panel of 12 cytokines ( IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF-α, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-γ) ability to predict treatment response in patients with intermediate/high risk NMIBC treated with intravesical BCG. 3.To develop a BCG prediction risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data.
What is the full name of this clinical trial?
IIT-BCGPREDICTIONASSAY: BCG Prediction Assay: A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients with Intermediate or High-Risk Non-Muscle InvasIVe Bladder Cancer